A Study on Management and Report of Adverse Event in Clinical Trials |
Lee, Se-Hyun
(Office of Human Research Protection, Catholic Medical Center, The Catholic University of Korea)
Kim, Yeong-In (Department of Neurology, Seoul St. Mary's Hospital, The Catholic University of Korea) Yim, Hyeon-Woo (Department of preventive medicine, College of Medicine, The Catholic University of Korea) Lee, Gwi-Hyang (Nicholas Cardinal Cheong Graduate School for Life, The Catholic University of Korea) Choe, Byung-In (Office of Human Research Protection, Catholic Medical Center, The Catholic University of Korea) |
1 | 식품의약품안전청. 임상시험 관련 순회교육. 임상시험 정책방향, 2011. |
2 | 식품의약품안전청. 약사법 시행규칙 별표3의2 의약품임상시험관리기준, 2011. |
3 | 식품의약품안전청 의약품본부 임상관리팀. 임상시험 이상반응보고 업무지침, 2007. |
4 | ICH-GCP E2A. Guideline for Industry. Clinical Safety Data Management: Definitions and standards for Expedited Reporting. |
5 | Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events [http://www.hhs.gov/ohrp/policy/advevntguid.html] |
6 | HY Shin. The suggestions for improving the institutional review board (IRB) in clinical trials: focusing on continuing management. J Korean Soc Clin Pharmacol Ther, 2011;19(1):5-13. (Korean) DOI ScienceOn |
7 | U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs-Improving Human Subject Protection January 2009 Procedural. |